RIBOCICLIB, Kisqali 200 mg film-coated tablets
IFG-01-2024
Approved small_molecule active
Quick answer
RIBOCICLIB, Kisqali 200 mg film-coated tablets for Hormone receptor–positive (HRpos)/human epidermal growth factor receptor 2–negative (HER2neg) early breast cancer at risk of recurrence is a Approved program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Hormone receptor–positive (HRpos)/human epidermal growth factor receptor 2–negative (HER2neg) early breast cancer at risk of recurrence
- Phase
- Approved
- Modality
- small_molecule
- Status
- active